# EDGAR Filing Document

**Accession Number:** 0001796280
**File Stem:** 0001193125-25-142046
**Filing Date:** 2025-6
**Character Count:** 2702
**Document Hash:** 8b934cbd2dcc7ba407df281f78d5dba1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-142046.hdr.sgml**: 20250722

**ACCESSION NUMBER**: 0001193125-25-142046

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250617

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Oric Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001796280
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 471787157
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 240 E. GRAND AVE.
- **STREET 2:** 2ND FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 388-5600

**MAIL ADDRESS:**
- **STREET 1:** 240 E. GRAND AVE.
- **STREET 2:** 2ND FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**ORIC Pharmaceuticals, Inc.** 

**240 E. Grand Ave, 2nd Floor** 

**South San Francisco, California 94080** 

June 17, 2025

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Tyler Howes

---

| | |
|:---|:---|
| **Re:** | **ORIC Pharmaceuticals, Inc.**  |

---

**Registration Statement on Form S-3**

**File No. 333-287949**

---

| | |
|:---|:---|
| **Acceleration** | **Request**  |

---

---

| | |
|:---|:---|
| **Requested Date:** | **June 20, 2025** |
| **Requested Time:** | **4:00 p.m. Eastern Time** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, ORIC Pharmaceuticals, Inc. (the "**Company**") hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-287949) (the "**Registration Statement**") be declared effective at the "Requested Date" and "Requested Time" set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with the Company's counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Amanda Urquiza at (650) 849-3032.

[*Signature page follows*]

------

---

| |
|:---|
| Sincerely, |
| **ORIC Pharmaceuticals, Inc.** |
| /s/ Jacob M. Chacko, M.D. |
| Jacob M. Chacko, M.D. |
| President and Chief Executive Officer |

---

cc: Christian Kuhlen, ORIC Pharmaceuticals, Inc.

Jennifer Knapp, Wilson Sonsini Goodrich & Rosati, P.C.

Amanda N. Urquiza, Wilson Sonsini Goodrich & Rosati, P.C.